Targeted delivery of doxorubicin into tumor cells by nanostructured lipid carriers conjugated to anti-EGFRvIII monoclonal antibody

References

• Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7:771–782.
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751–760.
   PubMed Web of Science ®Google Scholar
• Meng F, Zhong Y, Cheng R, et al. pH-sensitive polymeric nanoparticles for tumor-targeting doxorubicin delivery: concept and recent advances. Nanomedicine. 2014;9:487–499.
   PubMed Web of Science ®Google Scholar
• Mognetti B, Barberis A, Marino S, et al. In vitro enhancement of anticancer activity of paclitaxel by a Cremophor free cyclodextrin-based nanosponge formulation. J Incl Phenom Macrocycl Chem. 2012;74:201–210.
   Web of Science ®Google Scholar
• How CW, Abdullah R, Abbasalipourkabir R. Physicochemical properties of nanostructured lipid carriers as colloidal carrier system stabilized with polysorbate 20 and polysorbate 80. Afr J Biotechnol. 2011;10:1684–1689.
   Web of Science ®Google Scholar
• Gorjikhah F, Azizi Jalalian F, Salehi R, et al. Preparation and characterization of PLGA-beta-CD polymeric nanoparticles containing methotrexate and evaluation of their effects on T47D cell line. Artif Cell Nanomed Biotechnol. 2016;45:432–440.
   PubMed Web of Science ®Google Scholar
• Eatemadi A, Darabi M, Afraidooni L, et al. Comparison, synthesis and evaluation of anticancer drug-loaded polymeric nanoparticles on breast cancer cell lines. Artif Cell Nanomed Biotechnol. 2016;44:1008–1017.
   PubMed Web of Science ®Google Scholar
• Mishra B, Padaliya R, Patel RR. Exemestane encapsulated vitamin E-TPGS-polymeric nanoparticles: preparation, optimization, characterization, and in vitro cytotoxicity assessment. Artif Cell Nanomed Biotechnol. 2016;45:522–534.
   PubMed Web of Science ®Google Scholar
• Garg T, Rath G, Goyal AK. Inhalable chitosan nanoparticles as antitubercular drug carriers for an effective treatment of tuberculosis. Artif Cell Nanomed Biotechnol. 2016;44:997–1001.
   PubMed Web of Science ®Google Scholar
• Verma A, Uzun O, Hu Y, et al. Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nat Mater. 2008;7:588–595.
   PubMed Web of Science ®Google Scholar
• Laurencin M, Georgelin T, Malezieux B, et al. Interactions between giant unilamellar vesicles and charged core − shell magnetic nanoparticles. Langmuir. 2010;26:16025–16030.
   PubMed Web of Science ®Google Scholar
• Dif A, Henry E, Artzner F, et al. Interaction between water-soluble peptidic CdSe/ZnS nanocrystals and membranes: formation of hybrid vesicles and condensed lamellar phases. J Am Chem Soc. 2008;130:8289–8296.
   PubMed Web of Science ®Google Scholar
• Gao H, Yang Z, Zhang S, et al. Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci Rep. 2013;3:2534.
   PubMed Web of Science ®Google Scholar
• Sutradhar KB, Amin ML. Nanotechnology in cancer drug delivery and selective targeting. ISRN Nanotechnol. 2014;2014:12.
   Google Scholar
• Liu R, Kay BK, Jiang S, et al. Nanoparticle delivery: targeting and nonspecific binding. MRS Bull. 2009;34:432–440.
   Web of Science ®Google Scholar
• Master AM, Sen Gupta A. EGF receptor-targeted nanocarriers for enhanced cancer treatment. Nanomedicine (Lond). 2012;7:1895–1906.
   PubMed Web of Science ®Google Scholar
• Okamoto A, Asai T, Kato H, et al. Antibody-modified lipid nanoparticles for selective delivery of siRNA to tumors expressing membrane-anchored form of HB-EGF. Biochem Biophys Res Commun. 2014;449:460–465.
   PubMed Web of Science ®Google Scholar
• Jaiswal P, Gidwani B, Vyas A. Nanostructured lipid carriers and their current application in targeted drug delivery. Artif Cell Nanomed Biotechnol. 2016;44:27–40.
   PubMed Web of Science ®Google Scholar
• Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J. 2013;280:5350–5370.
   PubMed Web of Science ®Google Scholar
• Moscatello DK, Holgado-Madruga M, Godwin AK, et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 1995;55:5536–5539.
   PubMed Web of Science ®Google Scholar
• Abdolahpour S, Mahdieh N, Jamali Z, et al. Development of doxorubicin-loaded nanostructured lipid carriers: preparation, characterization, and in vitro evaluation on MCF-7 cell line. BioNanoScience 2017. [Epub ahead of print]. doi: 10.1007/s12668-016-0391-x
   Web of Science ®Google Scholar
• Wikstrand CJ, Hale LP, Batra SK, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 1995;55:3140–3148.
   PubMed Web of Science ®Google Scholar
• Moscatello DK, Montgomery RB, Sundareshan P, et al. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene. 1996;13:85–96.
   PubMed Web of Science ®Google Scholar
• Mohan P, Rapoport N. Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking. Mol Pharm. 2010;7:1959–1973.
   PubMed Web of Science ®Google Scholar
• Paknejad M. Monoclonal antibody A-EGFRvIII-f against epidermal growth factor receptor variant III. Monoclon Antib Immunodiag Immunother 2014;33:149.
   Google Scholar
• Wang R, Xiao R, Zeng Z, et al. Application of poly(ethylene glycol)-distearoylphosphatidylethanolamine (PEG-DSPE) block copolymers and their derivatives as nanomaterials in drug delivery. Int J Nanomed. 2012;7:4185–4198.
   PubMed Web of Science ®Google Scholar
• Modjtahedi H, Moscatello DK, Box G, et al. Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy. Int J Cancer. 2003;105:273–280.
   PubMed Web of Science ®Google Scholar
• Barua S, Yoo JW, Kolhar P, et al. Particle shape enhances specificity of antibody-displaying nanoparticles. Proc Natl Acad Sci USA. 2013;110:3270–3275.
   PubMed Web of Science ®Google Scholar
• Pathak A, Tanmay M, Murthy RSR. Development and characterization of docetaxel loaded anti-FGFR-1 modified solid lipid nanoparticles for breast cancer targeting. Int J Adv Pharm Biol Chem. 2012;1:381–387.
   Google Scholar
• Mlalila N, Swai H, Kalombo L, et al. Effects of spray-drying on w/o/w multiple emulsions prepared from a stearic acid matrix. Nanotechnol Sci Appl. 2014;7:105–112.
   PubMedGoogle Scholar
• van der Ende AE, Sathiyakumar V, Diaz R, et al. Linear release nanoparticle devices for advanced targeted cancer therapies with increased efficacy. Polym Chem. 2010;1:93–96.
   Web of Science ®Google Scholar
• Li Y, Kroger M, Liu WK. Endocytosis of PEGylated nanoparticles accompanied by structural and free energy changes of the grafted polyethylene glycol. Biomaterials. 2014;35:8467–8478.
   PubMed Web of Science ®Google Scholar
• Natarajan J, Baskaran M, Humtsoe LC, et al. Enhanced brain targeting efficacy of Olanzapine through solid lipid nanoparticles. Artif Cell Nanomed Biotechnol. 2016;45:364–371.
   PubMed Web of Science ®Google Scholar
• Minko T, Rodriguez-Rodriguez L, Pozharov V. Nanotechnology approaches for personalized treatment of multidrug resistant cancers. Adv Drug Deliv Rev. 2013;65:1880–1895.
   PubMed Web of Science ®Google Scholar
• Miglietta A, Cavalli R, Bocca C, et al. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int J Pharm. 2000;210:61–67.
   PubMed Web of Science ®Google Scholar
• Nguyen DH, Lee JS, Bae JW, et al. Targeted doxorubicin nanotherapy strongly suppressing growth of multidrug resistant tumor in mice. Int J Pharm. 2015;495:329–335.
   PubMed Web of Science ®Google Scholar
• Liu D, Liu F, Liu Z, et al. Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody. Mol Pharm. 2011;8:2291–2301.
   PubMed Web of Science ®Google Scholar
• Knight LC, Romano JE, Krynska B, et al. Binding and internalization of iron oxide nanoparticles targeted to nuclear oncoprotein. J Mol Biomark Diagn. 2010;1:102. doi:10.4172/2155-9929.1000102
   Google Scholar
• Han C, Li Y, Sun M, et al. Small peptide-modified nanostructured lipid carriers distribution and targeting to EGFR-overexpressing tumor in vivo. Artif Cell Nanomed Biotechnol. 2014;42:161–166.
   PubMed Web of Science ®Google Scholar
• Sharma N, Bhandari S, Deshmukh R, et al. Development and characterization of embelin-loaded nanolipid carriers for brain targeting. Artif Cell Nanomed Biotechnol 2016;45:409–413.
   PubMed Web of Science ®Google Scholar